CCO Oncology Podcast

Optimizing the Timing and Sequencing of Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer

Episode Summary

Listen to Joleen Hubbard, MD, and John L. Marshall, MD, discuss the use of key later-line treatment options for patients with mCRC, including optimal treatment sequencing and dosing and key adverse events.

Episode Notes

In this episode, Joleen Hubbard, MD, and John L. Marshall, MD, discuss use of the later-line treatment options regorafenib and TAS-102 for patients with mCRC, with topics including:

• Key data supporting the clinical use of these agents
• Optimal sequencing and timing of use
• Dosing considerations
• Key adverse events

Presenters:

Joleen Hubbard, MD
Associate Professor
Gastrointestinal Oncologist
Medical Oncology
Mayo Clinic
Rochester, Minnesota

John L. Marshall, MD
Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Content based on an online CME program supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

Link to full program:  BITLY NEEDED